These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583 [TBL] [Abstract][Full Text] [Related]
6. Correlation of the suppressive activity of a biological response modifier on the proliferation of peripheral blood mononuclear cells and the reduction of HIV titer. Vila LM; Ríos-Olivares E; Vila S; Ríos Z; Rivera E; Robles R; Reyes JC; Castillo X Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):981-8. PubMed ID: 9449530 [TBL] [Abstract][Full Text] [Related]
7. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721 [TBL] [Abstract][Full Text] [Related]
8. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Schafer EA; Venkatachari NJ; Ayyavoo V Antiviral Res; 2006 Dec; 72(3):224-32. PubMed ID: 16889838 [TBL] [Abstract][Full Text] [Related]
9. The dolabellane diterpene Dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptase enzyme. Cirne-Santos CC; Souza TM; Teixeira VL; Fontes CF; Rebello MA; Castello-Branco LR; Abreu CM; Tanuri A; Frugulhetti IC; Bou-Habib DC Antiviral Res; 2008 Jan; 77(1):64-71. PubMed ID: 17888523 [TBL] [Abstract][Full Text] [Related]
10. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083 [TBL] [Abstract][Full Text] [Related]
11. Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. Kashiwada Y; Wang HK; Nagao T; Kitanaka S; Yasuda I; Fujioka T; Yamagishi T; Cosentino LM; Kozuka M; Okabe H; Ikeshiro Y; Hu CQ; Yeh E; Lee KH J Nat Prod; 1998 Sep; 61(9):1090-5. PubMed ID: 9748372 [TBL] [Abstract][Full Text] [Related]
12. Filarial infections increase susceptibility to human immunodeficiency virus infection in peripheral blood mononuclear cells in vitro. Gopinath R; Ostrowski M; Justement SJ; Fauci AS; Nutman TB J Infect Dis; 2000 Dec; 182(6):1804-8. PubMed ID: 11069260 [TBL] [Abstract][Full Text] [Related]
13. [Correlation between HIV-inhibiting drug activity in human macrophages and clinical outcome]. Aquaro S; Balestra E; Panti S; Cenci A; Serra F; Francesconi M; Abdelahad D; Caliò R; Perno CF Clin Ter; 1998; 149(921):37-41. PubMed ID: 9621487 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii. Cirne-Santos CC; Teixeira VL; Castello-Branco LR; Frugulhetti IC; Bou-Habib DC Planta Med; 2006 Mar; 72(4):295-9. PubMed ID: 16557468 [TBL] [Abstract][Full Text] [Related]
15. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773 [TBL] [Abstract][Full Text] [Related]
16. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. Schläpfer E; Fischer M; Ott P; Speck RF AIDS; 2003 Jul; 17(11):1613-20. PubMed ID: 12853743 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies towards HIV-1 infection in macrophages. Perno CF; Svicher V; Schols D; Pollicita M; Balzarini J; Aquaro S Antiviral Res; 2006 Sep; 71(2-3):293-300. PubMed ID: 16806514 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601 [TBL] [Abstract][Full Text] [Related]
19. Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy. Fridkin M; Tsubery H; Tzehoval E; Vonsover A; Biondi L; Filira F; Rocchi R J Pept Sci; 2005 Jan; 11(1):37-44. PubMed ID: 15635725 [TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda K; Vela JE; Myrick F; Ray AS; Miller MD Antivir Ther; 2006; 11(3):377-84. PubMed ID: 16759055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]